Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Controlled substance category
|
| gptkbp:contrastsWith |
gptkb:Schedule_III_substances
gptkb:Schedule_II_substances gptkb:Schedule_IV_substances gptkb:Schedule_V_substances |
| gptkbp:criteria |
High potential for abuse
Lack of accepted safety for use under medical supervision No currently accepted medical use in treatment in the US |
| gptkbp:definedIn |
gptkb:United_States_Controlled_Substances_Act
|
| gptkbp:example |
gptkb:Heroin
gptkb:Methaqualone gptkb:Psilocybin gptkb:MDMA LSD Cannabis Peyote Khat |
| gptkbp:excludes |
Limited research use with special DEA license
|
| https://www.w3.org/2000/01/rdf-schema#label |
Schedule I substances
|
| gptkbp:legalStatus |
Illegal to manufacture, possess, or distribute in the US
|
| gptkbp:penalty |
Severe criminal penalties for violations
|
| gptkbp:regulates |
gptkb:Drug_Enforcement_Administration
|
| gptkbp:scheduleNumber |
I
|
| gptkbp:bfsParent |
gptkb:21_U.S.C._§_812
gptkb:21_U.S.C._§_841 gptkb:21_U.S._Code_§_841 |
| gptkbp:bfsLayer |
7
|